IBD Science for Patients

Tofacitinib: When ‘Less is More’ on Your Ulcerative Colitis Journey

When you are diagnosed with ulcerative colitis, a lifelong inflammatory bowel condition that causes sores and inflammation in your large intestine, the immediate goal is to get your symptoms under control. Modern oral therapies, such as a Janus kinase (JAK) inhibitor called tofacitinib, have been a game-changer. Janus kinase inhibitors act as tiny “off-switches” inside your immune cells, blocking the specific chemical pathways that tell your body to create inflammation.

However, once you achieve stable remission, which means your symptoms have disappeared and your gut has healed, you and your doctor might ask a crucial question: do I need to stay on this maximum dose forever, or can I safely reduce it to lower the risk of side effects?

The long-term follow-up results from a major clinical trial called the RIVETING trial have provided the scientific evidence needed to answer this question.

Inside the RIVETING Trial: A Close Look at the Numbers

This was a large-scale phase 3b/4 double-blind randomised trial. In the medical world, a “double-blind randomised trial” is the gold standard for clinical research because neither the patients nor the doctors know who is taking which dose, preventing any unconscious bias. A “phase 3b/4” status means this study evaluated how the drug performs in real-world scenarios over a longer period after it has already been approved for general use.

The study followed 140 patients with ulcerative colitis who had achieved exceptionally stable remission. To qualify for the trial, these patients had to meet three strict safety criteria:

  1. They had to be in stable remission for at least six months.
  2. They had to be completely free of corticosteroids, such as prednisolone, for at least four weeks.
  3. They had to have been taking the standard, high maintenance dose of tofacitinib (10 mg twice daily) for at least two years.

The researchers randomised these 140 patients into two equal groups for a long-term follow-up that ran for 30 months (two and a half years). Half of the patients remained on their high dose of 10 mg twice daily, while the other half stepped down to a reduced dose of 5 mg twice daily.

Can You Maintain Remission on a Lower Dose?

The RIVETING trial revealed that reducing your dose is a highly viable option, though staying on the higher dose offers slightly stronger protection against a flare-up:

  • The Success Rates: At the end of the 30-month study, 50 per cent of the patients who reduced their dose to 5 mg twice daily successfully maintained their remission. In comparison, 62.9 per cent of the patients who stayed on the higher 10 mg twice-daily dose remained in stable remission.
  • Predicting Your Success: The study used advanced data analysis to find out who was most likely to succeed on the lower dose. They found that patients were much more likely to stay healthy on the 5 mg dose if they had a baseline endoscopic subscore of 0. This is a medical grade given during a colonoscopy (a camera inspection of your bowel) where 0 means your gut lining looks completely normal and healthy, whereas a score of 1 indicates very mild, inactive redness.
  • The Biologic Factor: Patients were also far more successful at maintaining the lower dose if they had not previously experienced tumor necrosis factor inhibitor (TNFi) failure. TNFi failure is when traditional biologic injections (like infliximab or adalimumab, which target a specific inflammatory protein called TNF-alpha) have failed to control your disease in the past.

The Safety Payoff: Why Lowering Your Dose Matters

The main reason to consider stepping down your dose is safety. While tofacitinib has an excellent real-world safety profile, taking a higher dose of any immunosuppressant over several years naturally carries a slightly higher risk of infections.

The RIVETING researchers noted that the rates of serious infections and herpes zoster (shingles, a painful skin rash caused by a reactivation of the chickenpox virus) were numerically higher in patients taking the 10 mg twice-daily dose compared to those on the reduced 5 mg twice-daily dose. Stepping down your medicine therefore offers a direct safety benefit by protecting you from these uncomfortable viral side effects.

What Happens If You Relapse? Your Safety Net

One of the most reassuring findings from this two and a half year study is what happens if you do experience a relapse after lowering your dose.

If a patient’s symptoms began to return on the 5 mg dose, doctors used a strategy called dose-escalation, simply meaning they put the patient back up to the original 10 mg twice-daily dose.

The trial showed that this safety net is incredibly effective: 11 out of 14 patients (78.6 per cent) who relapsed successfully recaptured their remission after going back to the higher dose, taking a median of 4.8 months to get their gut completely quiet again.

Why This Matters to You as a Patient

If you are currently taking tofacitinib to manage your ulcerative colitis, this long-term study is an empowering roadmap for your future care:

  1. Science-Backed Personalisation: This study gives you the scientific proof that your treatment does not have to be “one-size-fits-all.” Rather than staying on a high dose indefinitely, you can work with your doctor to personalise your treatment plan based on how well your body is doing.
  2. Aiming for an Endoscopic Score of 0: Knowing that patients with a completely healthy gut lining (endoscopic score of 0) did best on the lower dose gives you a clear goal. It highlights why checking your gut wall through regular monitoring is so important before making any changes.
  3. A Safe, Reassuring Backup Plan: Deciding to lower your dose can feel scary because no one wants to invite a flare-up back into their life. But this research offers massive peace of mind: if your body does struggle on the lower dose, simply going back to the 10 mg dose has a nearly 79 per cent success rate of getting you safely back into remission.

Always speak to your gastroenterology team before adjusting your medication. This landmark study provides the perfect conversation starter for your next clinic visit, helping you work together to keep your gut healthy while minimising your daily medicine.

Explore the Research

Leave a comment